Bristol-Myers Squibb Co (BUE:BMY) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:BMY Bristol-Myers Squibb Co BUE:BMY
56 GF Score
Price ARS30,980.00
GF Value ARS28,025.90
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bristol-Myers Squibb Co Valuation Rank Related Terms

BUE:BMY
56GF Score
Bristol-Myers Squibb Co BUE:BMY
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bristol-Myers Squibb Co (BUE:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of ARS30,980.00 is trading 10.5% above its estimated GF Value™ of ARS28,025.90. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for BUE:BMY:

  • Valuation Rank:
  • GF Value™: ARS28,025.90 vs. price of ARS30,980.00 (10.5% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the BUE:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
56GF Score

Get the complete analysis for BUE:BMY

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS30,980.00
Price
ARS28,025.90
GF Value